China Money Network
Login
Join

Boyu Capital Leads $120M Series B Round Into Oncology Medicine Developer Antengene

  • January 2, 2019 — 11:45 CST

This Data Is Locked!

This area is available only to Subscribers.

Antengene Corporation, a Chinese clinical-stage therapeutics company focused on oncology, has secured a US$120 million in series B round of financing, jointly led by Boyu... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: